GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills, Compounding & Supply-Chain Stocks
.png)
By OneDayAdvisor Editorial Team | Published: October 14, 2026 | Last updated: October 16, 2026 Disclosure. This article is educational research, not investment, tax or medical advice. OneDayAdvisor is not a registered investment adviser, and nothing here is a recommendation to buy or sell any security. Company figures come from the sources listed at the end; verify against primary filings before acting. For patient-side guidance on these medicines, see the OneDayMD GLP-1 resource hub . QUICK ANSWER GLP-1 investing in October 2026 has four layers: the two incumbents (Eli Lilly, with Q2 revenue up 48% to $23.0 billion, and Novo Nordisk, with adjusted sales up 7%), the oral-pill race (Wegovy pill vs Foundayo), the compounding crackdown, and picks-and-shovels suppliers. Growth is volume-led while per-patient prices fall, so the key questions are valuation, pipeline timing and policy, not whether demand exists. [1] [4] On this page 1. Market snapshot: the n...